Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks
On September 3, a caller asked whether to rotate out of artificial intelligence stocks and add to Eli…
Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions
AtaiBeckley’s lead program, BPL-003, is designed to provide durable relief from treatment-resistant depression Acquisition expands Lilly’s neuroscience pipeline…
/C O R R E C T I O N — Eli Lilly and Company/
In the news release, Lilly to present Alzheimer’s disease diagnostic and therapeutic research at AAIC 2026, including new…
Is Eli Lilly (LLY) One of Billionaire Cliff Asness’ Best Healthcare Stock Picks ?
Eli Lilly and Company (NYSE:LLY) is one of billionaire Cliff Asness’ top 10 healthcare stock picks. On June…
Is Eli Lilly and Company (LLY) Among the Best AI-Powered Healthcare Stocks to Buy According to Hedge Funds?
Eli Lilly and Company (NYSE:LLY) is among the Best Healthcare Stocks Stocks.On June 23, Reuters reported that Eli Lilly…
Lilly’s Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with chronic lymphocytic leukemia (CLL) across all lines of therapy
The positive opinion is based on results from the Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials, previously…
Lilly completes acquisition of Centessa Pharmaceuticals to advance treatments for sleep-wake disorders
INDIANAPOLIS, June 24, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced the successful completion of…
The Thriving Black Market for a Powerful Weight Loss Drug
Retatrutide, the most powerful weight-loss drug in development, is not expected to hit the U.S. market before next…
Zepbound (tirzepatide) and Shaquille O’Neal launch national campaign after NBA legend learns the obstructive sleep apnea he has lived with for years is treatable
In the national campaign Watch This, O’Neal gets real about living with moderate obstructive sleep apnea (OSA) and the…
FDA approves Lilly’s EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
EBGLYSS is now the only approved option that offers as few as six maintenance injections per year with…
LLY Stock: Foundayo Data Bolsters Weight-Loss Maintenance Case
Shares of Eli Lilly and Company NYSE: LLY, the world’s most valuable pharmaceutical stock, started 2026 in a…
Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
Phase 3 LIBRETTO-432 study evaluating Retevmo (selpercatinib) as adjuvant therapy in RET fusion-positive NSCLC to be featured in…